2023年7月17日，复宏汉霖（2696.HK）宣布张文杰先生因工作重心调整辞任公司首席执行官职务，继续担任公司董事长、执行董事等职务。同时，经董事会审议通过，朱俊先生接任公司首席执行官，作为首席执行官、总裁兼首席财务官进行公司日常管理，并提名其为执行董事，待股东大会批准后正式生效。张文杰先生于2019年3月加入复宏汉霖，组织搭建自主商业化运营团队，在其领导的管理团队的带领下，公司成功从biotech进化为biopharma，在中国成功上市5款产品，海外上市1款产品，累计造福全球逾44万名患者。2023年上半年，复宏汉霖进一步优化提速，加速自身“造血”，以持续坚定的自我超越实现了首个半年度盈利，不仅成功打通公司研产销正循环，也为推动中国生物医药行业发展注入强大的信心。

复宏汉霖董事长兼执行董事张文杰表示

复宏汉霖已成功发展成为一个超过3000人的国际化生物制药公司，建立了完善的覆盖研发、生产及商业运营的一体化生物制药平台。我谨代表复宏汉霖感谢长期以来股东的信任，董事会的支持，以及团队的贡献与努力。近年来，复宏汉霖持续不断完善团队建设，以朱俊为代表的多名优秀管理人才陆续加入复宏汉霖。朱俊深耕医疗领域超过20年，具有丰富的行业经验和领先的国际视野，在创新研发、国际战略及全球运营管理方面有着深刻的理解，过去两年多的时间里，有力地推动公司进一步深化产品管线价值，布局全球市场。我很高兴朱俊接任首席执行官一职，我们将持续聚焦未满足的临床需求，为全球患者提供更多可负担的高品质生物药。

复宏汉霖首席执行官、总裁兼首席财务官朱俊表示

非常荣幸接任复宏汉霖首席执行官，感谢文杰及董事会对我的信任。在文杰的领导下，复宏汉霖成功将多款高品质生物药推向全球市场，为公司长期发展奠定了稳定坚实的基础。未来，我们将继续以高质量发展和精益运营为导向，进一步完善“研产销”一体化平台建设，积极提升创新能力和全球竞争力，深化产品创新、市场拓展和国际合作，共同创造复宏汉霖的长期价值。

关于复宏汉霖

复宏汉霖（2696.HK）是一家国际化的创新生物制药公司，致力于为全球患者提供可负担的高品质生物药，产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域，已在中国上市5款产品，在国际上市1款产品，18项适应症获批，3个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来，复宏汉霖已建成一体化生物制药平台，高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心，按照国际药品生产质量管理规范（GMP）标准进行生产和质量管控，不断夯实一体化综合生产平台，其中，上海徐汇基地已获得中国和欧盟GMP认证，松江基地（一）也已获得中国GMP认证。

复宏汉霖前瞻性布局了一个多元化、高质量的产品管线，涵盖20多种创新单克隆抗体，并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。继国内首个生物类似药汉利康®（利妥昔单抗）、中国首个自主研发的中欧双批单抗药物汉曲优®（曲妥珠单抗，欧洲商品名：Zercepac®，澳大利亚商品名：Tuzucip®和Trastucip®）、汉达远®（阿达木单抗）和汉贝泰®（贝伐珠单抗）相继获批上市，创新产品汉斯状®（斯鲁利单抗）已获批用于治疗微卫星高度不稳定（MSI-H）实体瘤、鳞状非小细胞肺癌和广泛期小细胞肺癌，成为全球首个获批一线治疗小细胞肺癌的抗PD-1单抗，其食管鳞状细胞癌适应症的上市注册申请也正在审评中。公司亦同步就16个产品在全球范围内开展30多项临床试验，对外授权全面覆盖欧美主流生物药市场和众多新兴市场。

Mr. Jason Zhu Succeeds as Chief Executive Officer and Mr. Wenjie Zhang Serves as Chairman of Henlius

Shanghai, China, July 17th, 2023 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that Mr. Wenjie Zhang has resigned as Chief Executive Officer (CEO) and will maintain his role as Chairman and Executive Director due to work focus adjustment. The Board of Directors has unanimously elected Mr. Jason Zhu, the current President, and Chief Financial Officer (CFO), to succeed as CEO in charge of the company's management, and nominated Mr. Zhu as Executive Director, which will be effective upon the approval at the subsequent shareholders' meeting.

Mr. Zhang joined in March 2019 to build the commercial operation team. Under the leadership of him and his management team, the company has evolved from a biotech to a biopharma firm with several key milestones. It successfully launched five products in China and one in overseas markets, benefiting over 440,000 patients worldwide. In the first half of 2023, with further business iterations, Henlius achieved profitability for the first time in six months, meaning it has successfully entered a positive cycle of research and development, manufacturing, and commercialisation, also bringing strong confidence into driving the development of the Chinese biopharmaceutical industry.

Mr. Wenjie Zhang, Chairman, and Executive Director of Henlius, stated, "Henlius has successfully grown into an international biopharmaceutical company with over 3,000 employees, establishing a comprehensively integrated biopharmaceutical platform across research and development, manufacturing, and commercialisation. On behalf of Henlius, I would like to express my gratitude for the trust of shareholders, the board of directors' support, and the team's contributions and efforts. In recent years, Henlius has continued improving its team by attracting outstanding management talents, including Mr. Jason Zhu, who has over 20 years of dedicated experience in the healthcare industry. Jason has acquired extensive industry knowledge and a forward-thinking global perspective, also having a deep understanding of innovation research and development, international strategy, and global operations management. Over the past two years, he has made significant contributions to increasing the value of our product pipeline and expanding our global market presence. I am delighted that Jason takes on the role of CEO. We will continue to focus on addressing unmet clinical needs and provide more affordable and high-quality products for patients worldwide."

Mr. Jason Zhu, CEO, President, and CFO of Henlius said, "I am truly honored to succeed as the CEO of Henlius, and I appreciate the confidence that both Wenjie and the Board of Directors have in me. Under the remarkable leadership of Wenjie, Henlius has achieved great success in launching high-quality products to the global market, building a strong base for the company's long-term development. In the future, we will continue to prioritise high-quality development and lean operations, further optimise the integrated platform of research and development, manufacturing, and commercialisation, actively enhance our innovation capabilities and market competitiveness, and deepen product innovation, market development, and international partnerships to create long-term value."

About Henlius

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 1 has been approved for marketing in overseas markets, 18 indications are approved worldwide, and 3 marketing applications have been accepted for review in China, the U.S., and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialisation. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Plant certificated by China and the EU GMP and Songjiang First Plant certificated by China GMP.

Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®), the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Its NDA for the treatment of esophageal squamous cell carcinoma (ESCC) is under review. What's more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.